186 related articles for article (PubMed ID: 32596330)
1. Expression Atlas of FGF and FGFR Genes in Pancancer Uncovered Predictive Biomarkers for Clinical Trials of Selective FGFR Inhibitors.
Li Y; Wu L; Tao W; Wu D; Ma F; Li N
Biomed Res Int; 2020; 2020():5658904. PubMed ID: 32596330
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor (FGF), FGF receptor (FGFR), and cyclin D1 (CCND1) DNA methylation in head and neck squamous cell carcinomas is associated with transcriptional activity, gene amplification, human papillomavirus (HPV) status, and sensitivity to tyrosine kinase inhibitors.
Bao Y; Gabrielpillai J; Dietrich J; Zarbl R; Strieth S; Schröck F; Dietrich D
Clin Epigenetics; 2021 Dec; 13(1):228. PubMed ID: 34933671
[TBL] [Abstract][Full Text] [Related]
3. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
Katoh M
Int J Mol Med; 2016 Jul; 38(1):3-15. PubMed ID: 27245147
[TBL] [Abstract][Full Text] [Related]
4. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
[TBL] [Abstract][Full Text] [Related]
5. Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions.
Repetto M; Crimini E; Giugliano F; Morganti S; Belli C; Curigliano G
Expert Rev Clin Pharmacol; 2021 Oct; 14(10):1233-1252. PubMed ID: 34591728
[No Abstract] [Full Text] [Related]
6. Future applications of FGF/FGFR inhibitors in cancer.
Ghedini GC; Ronca R; Presta M; Giacomini A
Expert Rev Anticancer Ther; 2018 Sep; 18(9):861-872. PubMed ID: 29936878
[TBL] [Abstract][Full Text] [Related]
7. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.
Chell V; Balmanno K; Little AS; Wilson M; Andrews S; Blockley L; Hampson M; Gavine PR; Cook SJ
Oncogene; 2013 Jun; 32(25):3059-70. PubMed ID: 22869148
[TBL] [Abstract][Full Text] [Related]
8. Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors.
Sootome H; Fujita H; Ito K; Ochiiwa H; Fujioka Y; Ito K; Miura A; Sagara T; Ito S; Ohsawa H; Otsuki S; Funabashi K; Yashiro M; Matsuo K; Yonekura K; Hirai H
Cancer Res; 2020 Nov; 80(22):4986-4997. PubMed ID: 32973082
[TBL] [Abstract][Full Text] [Related]
9. Targeting the fibroblast growth factor receptor family in cancer.
Hallinan N; Finn S; Cuffe S; Rafee S; O'Byrne K; Gately K
Cancer Treat Rev; 2016 May; 46():51-62. PubMed ID: 27109926
[TBL] [Abstract][Full Text] [Related]
10. Recent developments and advances of FGFR as a potential target in cancer.
Xue WJ; Li MT; Chen L; Sun LP; Li YY
Future Med Chem; 2018 Sep; 10(17):2109-2126. PubMed ID: 30066580
[TBL] [Abstract][Full Text] [Related]
11. FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
Koole K; Brunen D; van Kempen PM; Noorlag R; de Bree R; Lieftink C; van Es RJ; Bernards R; Willems SM
Clin Cancer Res; 2016 Aug; 22(15):3884-93. PubMed ID: 26936917
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications.
Helsten T; Schwaederle M; Kurzrock R
Cancer Metastasis Rev; 2015 Sep; 34(3):479-96. PubMed ID: 26224133
[TBL] [Abstract][Full Text] [Related]
13. Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer.
Siegfried JM; Farooqui M; Rothenberger NJ; Dacic S; Stabile LP
Oncotarget; 2017 Apr; 8(15):24063-24076. PubMed ID: 28445992
[TBL] [Abstract][Full Text] [Related]
14. Small molecule inhibition of fibroblast growth factor receptors in cancer.
Liang G; Chen G; Wei X; Zhao Y; Li X
Cytokine Growth Factor Rev; 2013 Oct; 24(5):467-75. PubMed ID: 23830577
[TBL] [Abstract][Full Text] [Related]
15. FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy.
Quintanal-Villalonga Á; Ferrer I; Guruceaga E; Cirauqui C; Marrugal Á; Ojeda L; García S; Zugazagoitia J; Muñoz-Galván S; Lopez-Rios F; Montuenga L; Vicent S; Molina-Pinelo S; Carnero A; Paz-Ares L
EBioMedicine; 2020 Mar; 53():102683. PubMed ID: 32114392
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the FGF/FGFR System Induces Apoptosis in Lung Cancer Cells via c-Myc Downregulation and Oxidative Stress.
Giacomini A; Taranto S; Rezzola S; Matarazzo S; Grillo E; Bugatti M; Scotuzzi A; Guerra J; Di Trani M; Presta M; Ronca R
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33317057
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of Primary Drug Resistance in
Malchers F; Ercanoglu M; Schütte D; Castiglione R; Tischler V; Michels S; Dahmen I; Brägelmann J; Menon R; Heuckmann JM; George J; Ansén S; Sos ML; Soltermann A; Peifer M; Wolf J; Büttner R; Thomas RK
Clin Cancer Res; 2017 Sep; 23(18):5527-5536. PubMed ID: 28630215
[No Abstract] [Full Text] [Related]
18. Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors.
Salgia R
Cancer Med; 2014 Jun; 3(3):681-92. PubMed ID: 24711160
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors.
Hierro C; Rodon J; Tabernero J
Semin Oncol; 2015 Dec; 42(6):801-19. PubMed ID: 26615127
[TBL] [Abstract][Full Text] [Related]
20. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis.
Ronca R; Giacomini A; Rusnati M; Presta M
Expert Opin Ther Targets; 2015; 19(10):1361-77. PubMed ID: 26125971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
